跳转至内容
Merck
CN

SML3513

Sigma-Aldrich

Lorcaserin hydrochloride

≥98% (HPLC), 5-hydroxytryptamine receptor agonist, powder

别名:

(1R)-8-Chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine hydrochloride, (R)-8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride, (R)-8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine hydrochloride, APD 356 hydrochloride, APD-356 hydrochloride, APD356 hydrochloride

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C11H14ClN·HCl
化学文摘社编号:
分子量:
232.15
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.04
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Lorcaserin hydrochloride, ≥98% (HPLC)

质量水平

方案

≥98% (HPLC)

表单

powder

药品控制

USDEA Schedule IV

储存条件

desiccated

颜色

white to beige

溶解性

H2O: 2 mg/mL, clear

储存温度

-10 to -25°C

生化/生理作用

Lorcaserin is an orally active, potent and selective 5-hydroxytryptamine receptor (5-HT2C) agonist (human/rat Ki = 15 /29 nM) with 18- and 104-fold higher potency than 5-HT2A and 5-HT2B by cellular inositol phosphate accumulation assay (EC50 = 9, 168, 943 nM, respectively) and good selectivity over 5-HT1A/3/4C/5A/6/7 and a panel of 67 other GPCRs and ion channels. Chronic daily treatment to rats (4.5-18 mg/kg p.o. b.i.d.) maintained on a high fat diet causes reductions in food intake and body weight gain.
Orally active, potent and selective 5-hydroxytryptamine receptor (5-HT2C) agonist in vitro and in vivo.

免责声明

Hygroscopic

象形图

Health hazardExclamation mark

警示用语:

Warning

危险声明

危险分类

Acute Tox. 4 Oral - Carc. 2

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Chronic Lorcaserin Treatment Reverses the Nicotine Withdrawal-Induced Disruptions to Behavior and Maturation in Developing Neurons in the Hippocampus of Rats
International Journal of Molecular Sciences, 22(2), 868-868 (2021)
Yang He et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 41(26), 5734-5746 (2021-05-26)
Obesity is a serious global health problem because of its increasing prevalence and comorbidities, but its treatments are limited. The serotonin 2C receptor (5-HT2CR), a G-protein-coupled receptor, activates proopiomelanocortin (POMC) neurons in the arcuate nucleus of hypothalamus (ARH) to reduce
Lisa R Gerak et al.
Drug and alcohol dependence, 227, 108991-108991 (2021-09-06)
The opioid epidemic continues despite the availability of medications, including buprenorphine, for opioid use disorder (OUD); identifying novel and effective treatments is critical for decreasing the prevalence of OUD and ending this crisis. Buprenorphine alone does not markedly attenuate abuse-related
William J Thomsen et al.
The Journal of pharmacology and experimental therapeutics, 325(2), 577-587 (2008-02-07)
5-Hydroxytryptamine (5-HT)(2C) receptor agonists hold promise for the treatment of obesity. In this study, we describe the in vitro and in vivo characteristics of lorcaserin [(1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3 benzazepine], a selective, high affinity 5-HT(2C) full agonist. Lorcaserin bound to human and rat
Rayane I Tabbara et al.
Addiction biology, 26(5), e13040-e13040 (2021-05-01)
The serotonin (5-HT) system has been implicated in the pathophysiology of alcohol (ethanol; EtOH) use disorders. Lorcaserin, a 5-HT2C receptor agonist, attenuates drug self-administration in animal models. We investigated the effects of lorcaserin on EtOH intake using the drinking-in-the-dark (DID)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持